U.S. FDA approves Gilead blood cancer drug Zydelig

July 23, 2014 8:45 PM

3 0

U.S. FDA approves Gilead blood cancer drug Zydelig

(Reuters) - The U.S. Food and Drug Administration said on Wednesday it has approved Gilead Sciences Inc's Zydelig, a drug to treat three types of blood cancer.

The FDA approved the use of Zydelig in combination with Roche AG's Rituxan for patients with relapsed chronic lymphocytic leukemia (CLL).

Read more

To category page

Loading...